Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03686124RecruitingPhase 1/Phase 2
Tested immune therapy for certain HLA-A2 positive solid tumors
This trial studies an immune-based cancer treatment (IMA203/IMA203CD8) either alone or with nivolumab in people whose solid tumors have come back or will not respond to standard care. It may help by training the immune system to recognize and attack tumor cells that match the trial’s test requirements.
Stanford, CaliforniaAges 18 years+ - NCT03716089Recruiting
Laparoscopic surgery for stomach GIST by tumor site
This trial studies whether doing laparoscopic surgery for stomach GISTs (gastrointestinal stromal tumors) works and is safe when the tumor is in a “favorable” versus “unfavorable” location. You might be eligible if your tumor is confirmed as GIST and doctors expect to remove it completely using keyhole surgery.
Fuzhou, FujianAges 18–75 - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT03747133Recruiting
Radiation treatment for certain kidney tumors
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
Toronto, OntarioAges 18 years+ - NCT03778814RecruitingPhase 1
Personalized T-cell therapy for advanced lung or solid tumors
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
Guanzhou, GuangdongAges 18–75 - NCT03809585Recruiting
Study of iris tumors and healthy eyes
This observational study looks at eyes with iris tumors and compares them to eyes without iris problems. The goal is to better understand how iris circulation and related eye measurements differ, which may help future care.
Portland, OregonAges 18 years+ - NCT03818412Recruiting
Liquid biopsy for soft tissue sarcoma
This study checks if a blood test can detect DNA from soft tissue sarcomas. The goal is to see if circulating tumor DNA can help doctors monitor the disease and plan treatment.
Toronto, OntarioAges 18 years+ - NCT03823144Recruiting
Imaging small live tumor details during surgery
This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.
Jacksonville, FloridaAges 18 years+ - NCT03838042RecruitingPhase 1/Phase 2
Testing nivolumab plus entinostat for high-risk childhood cancers
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
Randwick, New South WalesAges 2–21 - NCT03842085RecruitingPhase 1
MBS301 drug study for HER2-positive advanced cancers
This Phase 1 study tests MBS301, a new treatment, for people with HER2-positive advanced solid tumors. It mainly looks at safety and how the drug works, especially for cancers that have returned or spread.
ZhengzhouAges 18 years+ - NCT03866525RecruitingPhase 1/Phase 2
Test an oncolytic virus treatment for solid tumors
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
Beijing, Beijing MunicipalityAges 18–75 - NCT03943004RecruitingPhase 1
Study drug DFP-14927 for advanced solid tumors
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Los Angeles, CaliforniaAges 18 years+ - NCT03967834Recruiting
Study of immune features in rare soft tissue sarcoma
This study looks at immune system “fingerprints” using tumor tissue from people with rare soft tissue sarcoma. It may help researchers understand what drives these cancers and guide future treatments.
BesançonAges 18 years+ - NCT04796012RecruitingPhase 1/Phase 2
Atezolizumab plus chemo for children with recurrent solid tumors
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
Chicago, IllinoisAges 6 months–30 years - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT07702162RecruitingPhase 1
Testing PA5 in advanced solid tumors
This trial tests a new drug called PA5 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if PA5 is safe and how well it works against these cancers.
Fuzhou, FujianAges 18 years+ - NCT05533697RecruitingPhase 1/Phase 2
mRNA medicine with or without immunotherapy for advanced solid cancers
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Los Angeles, CaliforniaAges 12 years+ - NCT04033497Recruiting
MRI study to tell tumor from dead tissue after brain radiation
This study uses MRI scans to figure out whether an enlarging spot in the brain after stereotactic (focused) radiation is still living tumor or dead tissue. It may help doctors better understand what’s happening after radiation and guide next treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT04068155Recruiting
Radiation device for certain skin cancers you can treat locally
This trial tests a radiation-emitting device placed near the tumor to treat certain malignant skin cancers that can be fully covered. It may help shrink or control the cancer at the skin site where the device is applied.
GrenobleAges 18 years+ - NCT04084067RecruitingPhase 1
ICG dye helps surgeons remove tumors
This early-phase study tests whether a special dye can help doctors see a tumor more clearly during surgery in children and young people. If you have a solid tumor or certain lymphomas that need removal, the dye may help guide the surgeon to the right tissue.
Memphis, TennesseeAges Any age - NCT04081701RecruitingPhase 4
Ga-68 DOTATATE PET/MRI for somatostatin-receptor brain tumors
This trial tests how well a special scan (Ga-68 DOTATATE PET combined with MRI) helps diagnose and guide treatment for certain brain tumors that have somatostatin receptors. It may help doctors better find tumor recurrence or remaining tumor after treatment.
New York, New YorkAges 18–100 - NCT04095299RecruitingPhase 3
Standard vs high-dose radiotherapy for rectal cancer
This Phase 3 trial compares standard-dose and higher-dose radiotherapy given along with chemotherapy in people with rectal cancer. The goal is to see whether a higher dose can improve rectal cancer outcomes while keeping the rectum functioning and avoiding too much harm.
AalborgAges 18 years+ - NCT04099290Recruiting
Blood DNA test in newly diagnosed head and neck cancer
This study looks at “circulating tumor DNA” (tumor DNA found in blood) in people with newly diagnosed, locally advanced head and neck squamous cell cancer. Researchers want to see how the blood DNA levels relate to the cancer and how it may guide treatment after surgery.
Chapel Hill, North CarolinaAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.